Promising real-world risdiplam outcomes in children with SMA

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Oct 12 / Springer Healthcare

Promising real-world risdiplam outcomes in children with SMA

Neuroscience Spinal Muscular Atrophy WMS-2022

Description

Susana Quijano-Roy shares her real-world experience of risdiplam treatment in children with symptomatic spinal muscular atrophy, finding favorable short-term outcomes in most patients.

Follow us here

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.